Development of a Therapy for Smallpox Vaccinia and Monkeypox

Project: Research project

Description

We will receive compounds that inhibit binding of E3L to Z-DNA (through its N-terminal Z-DNA binding domain) from several research institutes. We will subsequently perform highthroughput screening of these compounds for their ability to inhibit vaccinia virus replication in the JC (murine mammary gland adenocarcinoma) cell line. Compounds (not to exceed 3) determined to successfully inhibit replication of wild-type vaccinia virus in cell culture will be further tested in mice (129/sv strain) for protection against wild-type vaccinia virus challenge. If appropriate, we will also test a number of compounds for their ability to inhibit binding of monkeypox virus E3L to Z-DNA in cell culture.
StatusFinished
Effective start/end date8/1/097/31/11

Funding

  • HHS-NIH: Center for Scientific Review (CSR): $629,874.00

Fingerprint

Monkeypox
Z-Form DNA
Vaccinia
Smallpox
Vaccinia virus
Monkeypox virus
Cell Culture Techniques
129 Strain Mouse
Human Mammary Glands
Virus Replication
Adenocarcinoma
Therapeutics
Cell Line